Skanska wins additional $116m contract for UVA’s Manning biotechnology institute in Virginia

Why has Skanska’s expanded contract for UVA’s biotechnology facility attracted institutional attention?

Skanska AB (STO: SKA-B), the Swedish construction and development group, has secured an additional USD 116 million contract from the University of Virginia to advance construction of the Paul and Diane Manning Institute of Biotechnology. Located in Charlottesville’s Fontaine Research Park, this strategic facility aims to transform translational research and biomedical innovation across the region. The add-on contract, signed in the third quarter of 2025, is now part of Skanska’s U.S. order bookings for that period. It builds upon an existing contract that already had Skanska leading the design and construction of the biotechnology institute, reinforcing its role as a preferred contractor for complex life sciences infrastructure in the U.S. higher education sector.

This announcement comes at a time when demand for institutional-grade biotechnology research hubs is increasing across the United States. Universities are racing to modernize their research capacity, drawing on philanthropic contributions, state funding, and strategic partnerships with the private sector. Analysts have noted that the latest contract expansion not only reflects Skanska’s technical execution capability but also demonstrates its positioning within an expanding niche: delivering high-performance, ESG-aligned biomedical facilities that support drug discovery, gene therapy development, and translational medicine.

How is the Paul and Diane Manning Institute of Biotechnology expected to reshape translational research in Virginia?

The Paul and Diane Manning Institute of Biotechnology is a flagship investment in Virginia’s scientific future. Upon completion, the five-story facility will span approximately 354,000 square feet, or 33,000 square meters, making it one of the most ambitious translational research complexes in the state. Its design includes modular, multi-use laboratory and support spaces, high-capacity core facilities, and dedicated collaboration zones for biotechnology startups and industry partners.

The institute is expected to host between 100 and 150 researchers, many of whom will engage in cutting-edge scientific work across domains such as cell and gene therapy, nanotechnology, drug delivery platforms, and immune engineering. The goal is to collapse the traditional distance between laboratory discovery and clinical application, allowing early-stage biomedical insights to be quickly tested, validated, and transferred into real-world therapies. The University of Virginia has indicated that this facility will serve as a physical and intellectual anchor for cross-sector partnerships, licensing agreements, and biotech venture formation.

Construction initially began in December 2023 and is slated for full completion by the fourth quarter of 2027. Partial occupancy is expected as early as late 2026, allowing UVA researchers and administrative staff to begin utilizing core infrastructure before the final delivery milestone. The project replaces an existing parking lot within Fontaine Research Park and includes significant adjacent upgrades, such as a new parking garage, conference center, public café, and a dedicated central energy plant to support sustainability and operational efficiency.

What funding sources are backing this biotech facility and what does the financial structure reveal?

The financing structure behind the Paul and Diane Manning Institute of Biotechnology represents one of the more diversified and resilient models in U.S. research infrastructure. Leading the funding was a USD 100 million philanthropic gift from Paul and Diane Manning, whose longstanding relationship with the University of Virginia has helped catalyze a broader vision for biotech-led economic development in the region. The university itself committed USD 150 million, demonstrating strong institutional buy-in and a clear mandate to accelerate translational research.

The Commonwealth of Virginia provided an additional USD 50 million through the 2022–2024 state budget, recognizing the project’s potential to elevate the state’s reputation in life sciences and advanced therapeutics. Two anonymous estate donors also contributed USD 50 million to support translational initiatives in fields such as oncology, neurodegeneration, and autoimmune disorders. These unrestricted estate gifts were earmarked for early-stage research, signaling philanthropic confidence in UVA’s ability to drive discovery beyond the lab bench.

The estimated total cost of the project, once auxiliary infrastructure such as roads and the Fontaine Central Energy Plant are included, exceeds USD 490 million. This figure reflects both the scale and complexity of delivering a next-generation biomedical hub. Financial analysts covering the construction and real estate sectors have suggested that the combined public-private-philanthropic structure provides stability and operational flexibility, which is particularly valuable given recent inflationary pressures in the U.S. construction market.

Why is Skanska being seen as a preferred contractor for biomedical research facilities in the U.S.?

For Skanska, the expanded UVA contract represents more than just incremental order growth—it strengthens the company’s credentials in a lucrative and strategically important segment. As more U.S. institutions invest in research infrastructure to support life sciences, bioinformatics, and AI-driven drug discovery, there is increased demand for developers who can deliver complex, future-proof buildings that meet regulatory, sustainability, and adaptability benchmarks. Skanska’s ability to win back-to-back contracts for the same project suggests a high degree of trust and performance satisfaction from the client.

The American construction market remains a critical driver of Skanska’s global performance, accounting for a significant portion of its revenue and backlog. In 2024, the company saw growing demand in verticals such as healthcare, education, and advanced research—sectors that tend to remain resilient even during broader economic cycles. The UVA biotechnology institute adds to Skanska’s growing portfolio of U.S.-based research and development facilities, many of which are designed to comply with LEED, WELL, and other ESG-aligned certifications.

Institutional investors have responded positively to the news. While the order size is not transformative in isolation, the strategic nature of the project adds long-duration visibility to Skanska’s U.S. pipeline. Analysts tracking construction sector performance have noted that winning projects like this contributes to predictable earnings, margin protection through scope clarity, and access to future bids in the academic research domain.

What are the long-term implications of UVA’s Manning Institute for regional economic development?

Beyond its academic and clinical significance, the Manning Institute is expected to serve as a catalyst for regional biotechnology innovation. The University of Virginia envisions the institute as a nucleus for public-private partnerships, clinical trials, and commercial spinouts. By providing shared lab infrastructure and modular research environments, the facility lowers barriers for startups and accelerates the path from intellectual property to viable therapeutic products.

Economic planners in Virginia are positioning the institute as a long-term jobs engine, particularly as the state works to diversify its innovation economy and reduce dependence on federal procurement and traditional manufacturing. By 2028, it is estimated that the biotechnology complex could generate hundreds of high-value jobs in Charlottesville and contribute materially to the state’s GDP through licensing revenue, venture investment, and healthcare innovation.

The project’s adjacency to UVA’s existing medical and research campuses further enhances its potential for integration and scale. Early-stage biotech firms will have direct access to university talent, clinical trial networks, and translational scientists, enabling faster iteration cycles and more efficient capital use. As such, the Manning Institute is being closely watched by regional economic development agencies, venture capital firms, and biopharma companies alike.

How does the timeline and facility design align with broader trends in U.S. biotech infrastructure?

The four-year construction timeline reflects the complexity of building facilities that require both laboratory-grade engineering and future flexibility. The design accommodates evolving research needs, with modular lab configurations, collaborative open-plan areas, and shared core equipment zones. This architectural approach matches recent trends in U.S. biotech infrastructure, where adaptability and sustainability are prioritized alongside speed-to-science.

Furthermore, the inclusion of a dedicated central energy plant and road infrastructure improvements aligns with integrated site planning seen in other high-profile U.S. biotech districts. These include the Innovation District in Philadelphia, the South San Francisco biotech cluster, and the Houston Medical Center. In each case, success depends on co-locating research, clinical, and manufacturing capabilities in a campus-like setting—an approach UVA is now replicating in Charlottesville with the help of Skanska.

While there are inherent risks in long-duration construction projects—including labor availability, material cost inflation, and zoning compliance—the presence of secured multi-source funding and phased development milestones lowers the risk profile. Institutional investors and construction market analysts have pointed to this project as a benchmark for how academic biotech infrastructure should be executed in the post-pandemic environment.